Invex Therapeutics | WA Innovation Ecosystem Navigator
About Invex Therapeutics
Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on repurposing the approved drug Exenatide, trademarked as Presendin™, for the treatment of neurological conditions involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke, and traumatic brain injury. The company is advancing clinical development of Presendin™ particularly for IIH. Invex aims to provide effective, evidence-based therapies for patients with these critical neurological disorders.
People
AS
Alexandra Sinclair
Founder
JL
Jason Loveridge
Founder
Ecosystem activity
2020
1 milestone
May
Raised $26.0MPOST IPO EQUITY
Valuation $4.0M
2019
2 milestones
July
IPO
March
SPINOUT with 1 investor
Is this your organisation?
Claim this profile to add your story, team and milestones.